In a follow-up analysis to the pivotal TOPAZ-1 study, which established the combination therapy of durvalumab (an immunotherapy drug) plus gemcitabine and cisplatin (GemCis, chemotherapy drugs) as the ...
The company's Phase I/II trial of the drug demonstrated a 46.5 percent overall response rate in patients with FGFR2 fusions or rearrangements.
In 2023, Sydney Towle, then 23, developed a bump on her abdomen that she could feel. When she exercised, she experienced a stinging in her stomach. Worried that she developed a hernia, Towle visited ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results